Patricia Van Arnum

Editorial Director, DCAT

patricia@dcat.org
Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members. She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees. Overall, she has more than 25 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.

LATEST

Does the Metaverse Have Potential in Pharma?
By

By
The metaverse is expected to have far-reaching applications in sectors such as healthcare, manufacturing, education/job training, and communications. What is the metaverse exactly, and what technologies and functions are in play?

Tracking Pharma Growth: Leading Therapeutic Sectors
By

By
Oncology continues to be the leading therapeutic sector in the global bio/pharma market on a value basis and in growth rates. What do the numbers show, and what other therapeutic sectors rank high in growth prospects?

CDMO Outsourcing Trends: Cell and Gene Therapies
By

By
Facing limited industry capacity, both large and small CDMOs continue to expand capacity for cell and gene therapies, but will demand for outsourced services by bio/pharma companies stay strong in the near term? 

Rising Energy & Raw Materials Costs: When Is Relief Coming?
By

By
Inflationary pressures, in the form of higher energy, raw materials, and shipping costs, have tightened margins across all industries, including the bio/pharma industry. When will relief be on the way? 

Sanofi’s Euroapi Launches as Stand-alone $1-Bn CDMO
By

By
Euroapi, a CDMO of small-molecule APIs spun off from Sanofi, has launched as a stand-alone publicly traded company. The CDMO projects 2022 revenues of $1 billion. What’s behind the new company?

What’s in Store for Generics/Biosimilars?
By

By
The fortunes of the generics/biosimilars market will rest on one of the largest patent cliffs upcoming over the next five years. What do the numbers show, and what key trends are in the mix?

How is the US Bio/Pharma Market Performing?
By

By
After reaching growth of 12% in 2021, in large measure due to COVID-19 products, growth in the US bio/pharma market is projected to moderate to pre-pandemic levels. What are the near-term outlook and key trends?

Geographic Supply Lines: API Manufacturing
By

By
What countries lead in API manufacturing facilities for generic drugs? The location of manufacturing facilities is an important consideration as policymakers evaluate ways to mitigate supply-chain vulnerabilities.

Will Public Disclosure of Sourcing and Mfg Info Improve the US Pharma Supply Chain?
By

By
At the request of Congress, the National Academies of Sciences, Engineering, and Medicine issued recommendations to improve the resiliency of the US pharma supply chain, including public disclosure of sourcing and manufacturing information. 

Supply-Chain Digitalization: Senior Executives Weigh in on the Opportunities and Challenges
By

By
Increasing the use of digital technologies, such as artificial intelligence, blockchain, and predictive analytics in supply-chain operations is a priority for many executives. Senior executives weigh in on the opportunities and challenges.